Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01122875 · ClinicalTrials.gov registry record · Phase 1

A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

A Phase 1 study of Multiple Myeloma, sponsored by Genentech.

Completed
Registry status
Phase 1
Development phase
14
Enrollment target
12
Study locations

NCT01122875 is a Phase 1 study of Multiple Myeloma that has completed, run by Genentech. The registered enrollment target is 14 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (97% lower). The trial reports 12 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01122875, a Phase 1 study of Multiple Myeloma, has completed, sponsored by Genentech.

COMPLETED
Registry status
Phase 1
Development phase
14 participants
Enrollment target
12
Study locations

Study Summary

This is a multicenter, open-label, dose-escalation study of MFGR1877S in patients with relapsed or refractory t(4;14)-positive multiple myeloma.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG MFGR1877S

Study Locations (12)

Michigan

  • - Ann Arbor
  • - Detroit

Arizona

  • - Scottsdale

Georgia

  • - Atlanta

Illinois

  • - Chicago

Massachusetts

  • - Boston

New Jersey

  • - Hackensack

New York

  • - New York

Texas

  • - Dallas

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2010-11
Est. Completion 2012-05
Phase Phase 1

Sponsor

Genentech

332 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01122875

The ClinicalTrials.gov registry entry for NCT01122875 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (97% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which MFGR1877S is the first listed.

NCT01122875 reports 12 study locations spanning 11 distinct geographic areas - top geographies include Michigan, Arizona, Georgia.

Frequently Asked Questions

What is clinical trial NCT01122875 about?

NCT01122875 is a clinical study titled "A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma". This is a multicenter, open-label, dose-escalation study of MFGR1877S in patients with relapsed or refractory t(4;14)-positive multiple myeloma.

What is the current status of trial NCT01122875?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2010-11. Estimated completion is 2012-05.

What conditions does trial NCT01122875 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT01122875?

The interventions under investigation include: MFGR1877S (DRUG).

Who is sponsoring clinical trial NCT01122875?

This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01122875 being conducted?

This trial has 12 study locations across Arizona, Georgia, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.